Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 2, 2010, Pages 103-108

  Kovarik, J M ^a   Bartlett, M ^a   Rordorf, C ^a   Antunes, M C ^a   Winter, S ^a   Marbach, P ^a   Van Marle, S ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b PRA International USA   (Netherlands)

Author keywords

Drug interactions; Everolimus; Immunomodulators; Protein kinase C; Sotrastaurin

Indexed keywords

EVEROLIMUS; SOTRASTAURIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; ELECTROCARDIOGRAM; HUMAN; HUMAN EXPERIMENT; LABORATORY PARAMETERS; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE CRAMP; NAUSEA; PARAMETERS OF MEASUREMENT AND ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

EID: 76749102357     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48103     Document Type: Article

References (8)

1. Bjornsson TD, Callaghan JT, Einholf HJ. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003; 43: 443-469.
2. Evenou J-P, Brinkmann V, Towbin H, et al. Enzymatic and cellular characterization of AEB071, a novel and selective protein kinase C inhibitor that blocks early T-cell activation, and its use to define the role of PKC in T-cells. (Abstract) Transplantation. 2006; 82 (Suppl): 1026.
3. Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Disposit. 2006; 27: 421-426.
4. Kuypers D. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant. 2008; 13: 11-18.
5. Meier-Kriesche HU, Li S, Gruessner RWG, et al. Immunosuppression: evolution in practice and trends 1994-2004. Am J Transplant. 2006; 6: 1111-1131.
6. Skvara H, Dawid M, Kleyn CE, et al. Potential therapeutic option for psoriasis with AEB071, a novel protein kinase C inhibitor. J Clin Invest. 2008; 118: 3151-3159.
7. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant. 2008; 8: 1972-1981.
8. United States Food and Drug Administration. Draft guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. 2006. http:// www.fda.gov/drugs/ guidancecomplianceregulatory information/guidances [17-Jun-2009].